The first patient has been enrolled in the EXPEDITE (Evaluate a next generation portable diagnostic platform for determination and immediate triage of emergency large vessel stroke) phase I clinical study at Erlanger Health System in Chattanooga, USA. The EXPEDITE study will evaluate the Neural Analytics’ portable monitoring platform for patients suffering an acute ischaemic stroke.
Despite significant advances for stroke treatment in recent years, a reliable diagnostic and monitoring method for first responders and emergency room physicians is unavailable to the clinical community. Current diagnostic assessments for stroke have limited accuracy and often result in lengthy delays to treatment which decrease outcomes for patients and increase the cost of care. The EXPEDITE study will examine Neural Analytics’ technology to assess patients for stroke and if rapid early assessment in the emergency room can expedite treatment and improve patient outcomes.
“The creation of a convenient, quantitative assessment system for the early detection of stroke is one of our most critical needs. We believe such a diagnostic tool will transform global patient management when it becomes available,” says Tom Devlin, medical director of Erlanger’s Southeast Regional Stroke Center and principal investigator of the study. “We are thrilled to be the first site in the world to begin evaluation of this promising technology, which uses ultrasound to rapidly assess blood flow in the brain and may help healthcare professionals determine if a patient is suffering a stroke.”
The study will enrol 150 patients who are suspected of having a large vessel occlusion (LVO) stroke and determine if Neural Analytics’ technology can assist clinicians in more rapidly assessing stroke risk in the emergency room setting. The study results are projected to be available in 2017.
Neural Analytics’ technology is currently under FDA and CE mark review for the monitoring of blood flow in the cerebral vasculature. It is not available for commercial use or sale.
